In-depth Analysis and Forecast Of The Vasculitis Market On The Global As Well As Regional Level 2024

"The Latest Research Report OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Vasculitis Market

Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behet's disease (BD). In 2014, there were 137,603 and 82,454 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan), respectively. Untreated, the organs and tissues affected by the damaged blood vessels do not get enough blood, which can lead to organ or tissue damage, or even death. J&J's Remicade was the first biologic in the vasculitis market, approved for BD in Japan in 2007. Other biologics approved for vasculitis include AbbVie's Humira for BD in Japan and Biogen/Roche's Rituxan for GPA/MPA in the 7MM. Several unmet needs still remain such as the development of drugs with improved safety and efficacy for use in both the induction and maintenance treatment settings . GlobalData expects the launch of six drugs during the 2014 to 2024 forecast period along with increased diagnosed patient numbers will drive the vasculitis market.

Highlights

Key Questions Answered

- How large an impact will biosimilars have on the vasculitis market? What do vasculitis specialists and key opinion leaders across the 7MM think about the evolving treatment landscape?
- What opportunities remain in the market for new product entrants?
- With six drug launches, five of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect the sales of induction and maintenance therapies?
- According to KOLs, what are the most important unmet needs in vasculitis? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
- What industry developments are likely to affect sales of the top-selling vasculitis drugs in the markets researched? Which is the largest growth market globally?

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/699484

Key Findings

- Biosimilars are expected to change the landscape for vasculitis and create pricing pressure in the vasculitis market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.
- Sales of immunosuppressants are expected to decline due to the introduction of novel biologics and small molecules to treat vasculitis.
- Several unmet needs are expected to remain after the forecast period, as all pipeline drugs are in development as induction therapies and maintenance therapies are lagging.
- With several major pharmaceutical companies involved in development of vasculitis products, the market will be dominated by Big Pharma who will leverage their R&D, manufacturing, and distribution networks.

Scope

- Overview of vasculitis, including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
- Annualized vasculitis market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the vasculitis market.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically BMSs Orencia, GSKs Benlysta and Nucala, Genentech/Roches Actemra, Celgenes Otezla, J&Js Remicade, and biosimilars (such as Celltrion/Hospira/Alvogens Inflectra/Remsima).
- Analysis of the current and future market competition in the global vasculitis market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

View Report @ https://www.marketresearchreports.biz/reports/699484/opportunityanalyzer-vasculitis-opportunity-analysis-and-forecast-to-2024-market-research-reports

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the vasculitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global vasculitis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global vasculitis market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/699484

Table of Contents

1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 21
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Types of Vasculitis 22
3.2 Etiology and Pathophysiology 23
3.2.1 Large Vessel Vasculitis 23
3.2.2 Kawasaki Disease 24
3.2.3 ANCA-Associated Small Vessel Vasculitis 25
3.2.4 Behets Disease 26
3.3 Symptoms 26
3.4 Disease Management 27
3.4.1 Classification Criteria 27
3.4.2 Disease Management Guidelines 28
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 36
4.4 Forecast Methodology 39
4.4.1 Sources Used 41
4.4.2 Sources Not Used 61
4.4.3 Forecast Assumptions and Methods 61
4.5 Epidemiological Forecast for Vasculitis, 2014-2024 85
4.5.1 Diagnosed Incident Cases of AAV 85
4.5.2 Diagnosed Prevalent Cases of AAV 87
4.5.3 Age-Standardized Incidence of AAV 89
4.5.4 Diagnosed Incident Cases of LVV - TA and GCA 92
4.5.5 Diagnosed Prevalent Cases of TA 94
4.5.6 Age-Standardized Incidence of LVV 96
4.5.7 Diagnosed Incident Cases of BD 98
4.5.8 Diagnosed Prevalent Cases of BD 100
4.5.9 Age-Standardized Incidence of BD 102
4.5.10 Diagnosed Incident Cases of KD 103
4.6 Discussion 105
4.6.1 Epidemiological Forecast Insight 105
4.6.2 Limitations of the Analysis 106
4.6.3 Strengths of the Analysis 107
5 Current Treatment Options 109
5.1 Overview 109
5.2 Product Profiles 111
5.2.1 Rituxan (Rituximab) 111
5.2.2 Humira (Adalimumab) 115
5.2.3 Remicade (Infliximab) 120
5.2.4 Mycophenolate Mofetil 125
5.2.5 Cyclophosphamide 129
5.2.6 Azathioprine 133
5.2.7 Methotrexate 137
5.2.8 Glucocorticoids 140
5.2.9 Intravenous Immunoglobulin 143
6 Unmet Needs Assessment and Opportunity Analysis 147
6.1 Overview 147
6.2 Improved Drug Efficacy and Safety in the Induction Therapy Setting 148
6.2.1 Unmet Need 148
6.2.2 Gap Analysis 149
6.2.3 Opportunity 151
6.3 Improved Drug Efficacy and Safety in the Maintenance Therapy Setting 151
6.3.1 Unmet Need 151
6.3.2 Gap Analysis 152
6.3.3 Opportunity 153
6.4 Biomarkers to Predict Responsiveness to Therapy 154
6.4.1 Unmet Need 154
6.4.2 Gap Analysis 154
6.4.3 Opportunity 154
6.5 Biomarkers to Predict Disease Relapse 155
6.5.1 Unmet Need 155
6.5.2 Gap Analysis 155
6.5.3 Opportunity 156
6.6 Early and Non-invasive Diagnosis of Vasculitis 156
6.6.1 Unmet Need 156
6.6.2 Gap Analysis 157
6.6.3 Opportunity 158
6.7 Adjunctive Therapy for the Treatment of KD 158
6.7.1 Unmet Need 158
6.7.2 Gap Analysis 160
6.7.3 Opportunity 161

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.